Abciximab plus heparin versus bivalirudin: ISAR-REACT-4
Objective:
Study:
Population:
Endpoint:
to evaluate the efficacy of abciximab plus heparin versus bivalirudin in
patients with non-ST-elevation MI undergoing PCI
multicenter double-blind randomized controlled trial
patients with non-ST segment elevation MI undergoing PCI
composite death, re-MI, urgent TVR or major bleeding at 30 days
Abciximab plus heparin versus bivalirudin: ISAR-REACT-4
Abciximab plus heparin versus bivalirudin: ISAR-REACT-4
Abciximab plus heparin versus bivalirudin: ISAR-REACT-4
Conclusion
abciximab plus heparin was associated with similar major adverse events as
bivalirudin. The major bleeding rate was lower with bivalirudin.
Kastrati NEJM 2011;365:1980-9